{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T09:50:56Z","timestamp":1776505856945,"version":"3.51.2"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1007\/s11033-012-1611-2","type":"journal-article","created":{"date-parts":[[2012,3,13]],"date-time":"2012-03-13T13:51:32Z","timestamp":1331646692000},"page":"7743-7753","source":"Crossref","is-referenced-by-count":39,"title":["Celecoxib inhibits growth of human autosomal dominant polycystic kidney cyst-lining epithelial cells through the VEGF\/Raf\/MAPK\/ERK signaling pathway"],"prefix":"10.1007","volume":"39","author":[{"given":"Tao","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nian-Song","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-Li","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Yang","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheng-Qiang","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang-Lin","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,3,14]]},"reference":[{"key":"1611_CR1","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2165\/00003495-200767160-00008","volume":"67","author":"JE Frampton","year":"2007","unstructured":"Frampton JE, Keating GM (2007) Celecoxib: a review of its use in the management of arthritis and acute pain. Drugs 67:2433\u20132472","journal-title":"Drugs"},{"key":"1611_CR2","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1002\/ana.21544","volume":"65","author":"BR Brooks","year":"2009","unstructured":"Brooks BR (2009) Managing amyotrophic lateral sclerosis: slowing disease progression and improving patient quality of life. Ann Neurol 65:S17\u2013S23","journal-title":"Ann Neurol"},{"key":"1611_CR3","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/ajg.2009.758","volume":"105","author":"PM Lynch","year":"2010","unstructured":"Lynch PM, Ayers GD, Hawk E, Richmond E, Eagle C, Woloj M et al (2010) The safety and efficacy of celecoxib in children with familial adenomatous polyposis. Am J Gastroenterol 105:1437\u20131443","journal-title":"Am J Gastroenterol"},{"key":"1611_CR4","first-page":"2659","volume":"30","author":"C Bocca","year":"2010","unstructured":"Bocca C, Bozzo F, Bassignana A, Miglietta A (2010) Antiproliferative effect of a novel nitro-oxy derivative of celecoxib in human colon cancer cells: role of COX-2 and nitric oxide. Anticancer Res 30:2659\u20132666","journal-title":"Anticancer Res"},{"key":"1611_CR5","doi-asserted-by":"crossref","first-page":"4542","DOI":"10.1158\/0008-5472.CAN-05-4428","volume":"66","author":"BS Reddy","year":"2006","unstructured":"Reddy BS, Wang CX, Kong AN, Khor TO, Zheng X, Steele VE et al (2006) Prevention of azoxymethane-induced colon cancer by combination of low doses of atorvastatin, aspirin, and celecoxib in F 344 rats. Cancer Res 66:4542\u20134546","journal-title":"Cancer Res"},{"key":"1611_CR6","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1097\/CAD.0b013e32833dada8","volume":"21","author":"SW Park","year":"2010","unstructured":"Park SW, Kim HS, Hah JW, Jeong WJ, Kim KH, Sung MW (2010) Celecoxib inhibits cell proliferation through the activation of ERK and p38 MAPK in head and neck squamous cell carcinoma cell lines. Anticancer Drugs 21:823\u2013830","journal-title":"Anticancer Drugs"},{"key":"1611_CR7","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ajh.20542","volume":"81","author":"GS Zhang","year":"2006","unstructured":"Zhang GS, Liu DS, Dai CW, Li RJ (2006) Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib. Am J Hematol 81:242\u2013255","journal-title":"Am J Hematol"},{"key":"1611_CR8","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1053\/jhep.2003.50380","volume":"38","author":"J Leng","year":"2003","unstructured":"Leng J, Han C, Demetris AJ, Michalopoulos GK, Wu T (2003) Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. Hepatology 38:756\u2013768","journal-title":"Hepatology"},{"key":"1611_CR9","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s10549-008-0229-5","volume":"116","author":"C Falandry","year":"2009","unstructured":"Falandry C, Debled M, Bachelot T, Delozier T, Cretin J, Romestaing P et al (2009) Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study. Breast Cancer Res Treat 116:501\u2013508","journal-title":"Breast Cancer Res Treat"},{"key":"1611_CR10","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1200\/JCO.2009.21.9410","volume":"27","author":"ES Antonarakis","year":"2009","unstructured":"Antonarakis ES, Heath EI, Walczak JR, Nelson WG, Fedor H, De Marzo AM et al (2009) Phase II, randomized, placebo-controlled trial of neoadjuvant celecoxib in men with clinically localized prostate cancer: evaluation of drug-specific biomarkers. J Clin Oncol 27:4986\u20134993","journal-title":"J Clin Oncol"},{"key":"1611_CR11","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1002\/cncr.21661","volume":"106","author":"BI Rini","year":"2006","unstructured":"Rini BI, Weinberg V, Dunlap S, Elchinoff A, Yu N, Bok R et al (2006) Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma. Cancer 106:566\u2013575","journal-title":"Cancer"},{"key":"1611_CR12","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00280-006-0347-x","volume":"60","author":"MK Krzyzanowska","year":"2007","unstructured":"Krzyzanowska MK, Tannock IF, Lockwood G, Knox J, Moore M, Bjarnason GA (2007) A phase II trial of continuous low-dose oral cyclophosphamide and celecoxib in patients with renal cell carcinoma. Cancer Chemother Pharmacol 60:135\u2013141","journal-title":"Cancer Chemother Pharmacol"},{"key":"1611_CR13","first-page":"86","volume":"14","author":"M Niemczyk","year":"2009","unstructured":"Niemczyk M, Niemczyk S, Paczek L (2009) Autosomal dominant polycystic kidney disease and transplantation. Ann Transplant 14:86\u201390","journal-title":"Ann Transplant"},{"key":"1611_CR14","first-page":"925","volume":"53","author":"DK Beebe","year":"1996","unstructured":"Beebe DK (1996) Autosomal dominant polycystic kidney disease. Am Fam Physician 53:925\u2013931","journal-title":"Am Fam Physician"},{"key":"1611_CR15","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1681\/ASN.V5122048","volume":"5","author":"GM Fick","year":"1995","unstructured":"Fick GM, Johnson AM, Hammond WS, Gabow PA (1995) Causes of death in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 5:2048\u20132056","journal-title":"J Am Soc Nephrol"},{"key":"1611_CR16","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1681\/ASN.V351119","volume":"3","author":"M Zeier","year":"1992","unstructured":"Zeier M, Geberth S, Gonzalo A, Chauveau D, Grunfeld JP, Ritz E (1992) The effect of uninephrectomy on progression of renal failure in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 3:1119\u20131123","journal-title":"J Am Soc Nephrol"},{"key":"1611_CR17","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y (2007) Autosomal dominant polycystic kidney disease. Lancet 369:1287\u20131301","journal-title":"Lancet"},{"key":"1611_CR18","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000254338","volume":"32","author":"RP Wuthrich","year":"2009","unstructured":"Wuthrich RP, Serra AL, Kistler AD (2009) Autosomal dominant polycystic kidney disease: new treatment options and how to test their efficacy. Kidney Blood Press Res 32:380\u2013387","journal-title":"Kidney Blood Press Res"},{"key":"1611_CR19","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1096\/fj.02-0460fje","volume":"17","author":"HM Aukema","year":"2003","unstructured":"Aukema HM, Adolphe J, Mishra S, Jiang J, Cuozzo FP, Ogborn MR (2003) Alterations in renal cytosolic phospholipase A2 and cyclooxygenases in polycystic kidney disease. FASEB J 17:298\u2013300","journal-title":"FASEB J"},{"key":"1611_CR20","doi-asserted-by":"crossref","first-page":"F821","DOI":"10.1152\/ajprenal.00257.2006","volume":"293","author":"D Sankaran","year":"2007","unstructured":"Sankaran D, Bankovic-Calic N, Ogborn MR, Crow G, Aukema HM (2007) Selective COX-2 inhibition markedly slows disease progression and attenuates altered prostanoid production in Han:SPRD-cy rats with inherited kidney disease. Am J Physiol Renal Physiol 293:F821\u2013F830","journal-title":"Am J Physiol Renal Physiol"},{"key":"1611_CR21","doi-asserted-by":"crossref","first-page":"10206","DOI":"10.1073\/pnas.93.19.10206","volume":"93","author":"SR Brill","year":"1996","unstructured":"Brill SR, Ross KE, Davidow CJ, Ye M, Grantham JJ, Caplan MJ (1996) Immunolocalization of ion transport proteins in human autosomal dominant polycystic kidney epithelial cells. Proc Natl Acad Sci USA 93:10206\u201310211","journal-title":"Proc Natl Acad Sci USA"},{"key":"1611_CR22","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1002\/ana.21812","volume":"67","author":"S Yu","year":"2010","unstructured":"Yu S, Patchev AV, Wu Y, Lu J, Holsboer F, Zhang JZ et al (2010) Depletion of the neural precursor cell pool by glucocorticoids. Ann Neurol 67:21\u201330","journal-title":"Ann Neurol"},{"key":"1611_CR23","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2119\/molmed.2009.00133","volume":"16","author":"A Levin","year":"2010","unstructured":"Levin A, Rosenbluh J, Hayouka Z, Friedler A, Loyter A (2010) Integration of HIV-1 DNA is regulated by interplay between viral Rev and cellular LEDGF\/p75 proteins. Mol Med 16:34\u201339","journal-title":"Mol Med"},{"key":"1611_CR24","doi-asserted-by":"crossref","unstructured":"Wang P, Guan YF, Du H, Zhai QW, Su DF, and Miao CY (2012) Induction of autophagy contributes to the neuroprotection of NAMPT in cerebral ischemic stroke. Autophagy 8:77\u201387","DOI":"10.4161\/auto.8.1.18274"},{"key":"1611_CR25","doi-asserted-by":"crossref","first-page":"523","DOI":"10.2119\/molmed.2010.000134","volume":"17","author":"P Wang","year":"2011","unstructured":"Wang P, Yang FJ, Du H, Guan YF, Xu TY, Xu XW et al (2011) Involvement of leptin receptor long isoform (LepRb)-STAT3 signaling pathway in brain fat mass- and obesity-associated (FTO) downregulation during energy restriction. Mol Med 17:523\u2013532","journal-title":"Mol Med"},{"key":"1611_CR26","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/j.1755-5949.2011.00265.x","volume":"17","author":"P Wang","year":"2011","unstructured":"Wang P, Tian WW, Song J, Guan YF, Miao CY (2011) Deficiency of NG2(+) cells contributes to the susceptibility of stroke-prone spontaneously hypertensive rats. CNS Neurosci Ther 17:327\u2013332","journal-title":"CNS Neurosci Ther"},{"key":"1611_CR27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2119\/molmed.2009.00121","volume":"16","author":"HJB Juan-Zhang","year":"2010","unstructured":"Juan-Zhang HJB, Li XX, Liu XB, Sun JP, Na-Li YZ, Ji XP (2010) ERK-MAPK signaling opposes rho-kinase to reduce cardiomyocyte apoptosis in heart ischemic preconditioning. Mol Med 16:307","journal-title":"Mol Med"},{"key":"1611_CR28","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/ana.21919","volume":"67","author":"Y Fan","year":"2010","unstructured":"Fan Y, Shen F, Frenzel T, Zhu W, Ye J, Liu J et al (2010) Endothelial progenitor cell transplantation improves long-term stroke outcome in mice. Ann Neurol 67:488\u2013497","journal-title":"Ann Neurol"},{"key":"1611_CR29","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/ana.22236","volume":"69","author":"P Wang","year":"2011","unstructured":"Wang P, Xu TY, Guan YF, Tian WW, Viollet B, Rui YC et al (2011) Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann Neurol 69:360\u2013374","journal-title":"Ann Neurol"},{"key":"1611_CR30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/ana.21944","volume":"67","author":"J Correale","year":"2010","unstructured":"Correale J, Villa A (2010) Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis. Ann Neurol 67:625\u2013638","journal-title":"Ann Neurol"},{"key":"1611_CR31","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1177\/106689690401200215","volume":"12","author":"N Kuroda","year":"2004","unstructured":"Kuroda N, Satake H, Miyazaki E, Hayashi Y, Hiroi M, Enzan H (2004) Collecting duct carcinoma exhibiting diastase-resistant PAS-positive globular cytoplasmic inclusions and rhabdoid features arising in adult polycystic kidney disease: a case report. Int J Surg Pathol 12:171\u2013177","journal-title":"Int J Surg Pathol"},{"key":"1611_CR32","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/cvr\/cvn288","volume":"81","author":"P Wang","year":"2009","unstructured":"Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY (2009) Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 81:370\u2013380","journal-title":"Cardiovasc Res"},{"key":"1611_CR33","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0006-2952(01)00857-7","volume":"63","author":"A Raz","year":"2002","unstructured":"Raz A (2002) Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem Pharmacol 63:343\u2013347","journal-title":"Biochem Pharmacol"},{"key":"1611_CR34","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/ijc.20878","volume":"115","author":"DS Dandekar","year":"2005","unstructured":"Dandekar DS, Lopez M, Carey RI, Lokeshwar BL (2005) Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells. Int J Cancer 115:484\u2013492","journal-title":"Int J Cancer"},{"key":"1611_CR35","doi-asserted-by":"crossref","first-page":"407","DOI":"10.4161\/cbt.4.4.1618","volume":"4","author":"SY Sun","year":"2005","unstructured":"Sun SY, Schroeder CP, Yue P, Lotan D, Hong WK, Lotan R (2005) Enhanced growth inhibition and apoptosis induction in NSCLC cell lines by combination of celecoxib and 4HPR at clinically relevant concentrations. Cancer Biol Ther 4:407\u2013413","journal-title":"Cancer Biol Ther"},{"key":"1611_CR36","doi-asserted-by":"crossref","first-page":"C419","DOI":"10.1152\/ajpcell.00038.2007","volume":"293","author":"CR Amura","year":"2007","unstructured":"Amura CR, Brodsky KS, Groff R, Gattone VH, Voelkel NF, Doctor RB (2007) VEGF receptor inhibition blocks liver cyst growth in pkd2 (WS25\/-) mice. Am J Physiol Cell Physiol 293:C419\u2013C428","journal-title":"Am J Physiol Cell Physiol"},{"key":"1611_CR37","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1523-1755.2005.00155.x","volume":"67","author":"Y Tao","year":"2005","unstructured":"Tao Y, Kim J, Stanley M, He Z, Faubel S, Schrier RW et al (2005) Pathways of caspase-mediated apoptosis in autosomal-dominant polycystic kidney disease (ADPKD). Kidney Int 67:909\u2013919","journal-title":"Kidney Int"},{"key":"1611_CR38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1535-6108(03)00189-2","volume":"4","author":"DA Tuveson","year":"2003","unstructured":"Tuveson DA, Weber BL, Herlyn M (2003) BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4:95\u201398","journal-title":"Cancer Cell"},{"key":"1611_CR39","doi-asserted-by":"crossref","first-page":"6771","DOI":"10.1200\/JCO.2005.08.036","volume":"23","author":"M Beeram","year":"2005","unstructured":"Beeram M, Patnaik A, Rowinsky EK (2005) Raf: a strategic target for therapeutic development against cancer. J Clin Oncol 23:6771\u20136790","journal-title":"J Clin Oncol"},{"key":"1611_CR40","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S et al (2002) Mutations of the BRAF gene in human cancer. Nature 417:949\u2013954","journal-title":"Nature"},{"key":"1611_CR41","first-page":"469","volume":"22","author":"F Chang","year":"2003","unstructured":"Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL et al (2003) Regulation of cell cycle progression and apoptosis by the Ras\/Raf\/MEK\/ERK pathway. Intl J Oncol 22:469\u2013480","journal-title":"Intl J Oncol"},{"key":"1611_CR42","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1038\/sj.onc.1202581","volume":"17","author":"G Nunez","year":"1998","unstructured":"Nunez G, Benedict MA, Hu Y, Inohara N (1998) Caspases: the proteases of the apoptotic pathway. Oncogene 17:3237\u20133245","journal-title":"Oncogene"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s11033-012-1611-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,21]],"date-time":"2024-04-21T10:44:32Z","timestamp":1713696272000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11033-012-1611-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,14]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["1611"],"URL":"https:\/\/doi.org\/10.1007\/s11033-012-1611-2","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,14]]}}}